Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Switchable Genes

Many genes that exist naturally in the body turn on and off when needed; otherwise they would crank out superfluous proteins nonstop. But the artificial genes that are injected to treat disease generally are simpler constructs and are always “on,” starting protein production soon after they reach the bloodstream. Now, researchers at SRI International in Menlo Park, CA, have constructed an artificial gene with an “off” switch.

SRI’s experimental gene directs the production of proteins responsible for growing new blood vessels. Persistent low levels of oxygen in cardiac muscle-often an early warning of clogged blood vessels that can cause heart attack-turn the gene on, initiating the production of blood vessels. Over time, these new vessels remedy the oxygen shortage. When the oxygen level returns to normal, the gene switches “off.” SRI has secured two patents on the unique DNA sequence that acts as the gene’s switch.

0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me